Avoiding Diabetes After Pregnancy Trial

NCT ID: NCT01923350

Last Updated: 2013-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Avoiding Diabetes After Pregnancy Trial (ADAPT) study was designed to test the effectiveness of interventions that potentially increase the adoption of Diabetes Prevention Program (DPP) elements by women who had a pregnancy with gestational diabetes mellitus (GDM).

The study was conducted as an integrated trial with two separate arms: one to facilitate weight reduction and the other to increase diabetes testing.

There were two hypotheses:

1. Women in the testing intervention will be more likely to have received a diabetes test within the 6 months post-intervention than women in the control group.
2. Women in the weight reduction intervention will have lost more weight at the 6-month and 9-month follow-up than women in the control group.

The primary study aim was to determine the efficacy of a system of interactive technology-based supports to prompt women with a history of gestational diabetes to take steps to prevent diabetes. The secondary aims were focused on women's engagement:

* To evaluate the impact of the weight reduction intervention in terms of participant engagement with the interactive technology-based supports.
* To evaluate changes in the women's perception of their personal diabetes risk following after exposure to information about diabetes risk following a pregnancy with GDM.
* To identify the determinants and motivators of and barriers to diabetes testing in the 6- to 12-week postpartum period and thereafter, using the Health Belief model to guide the study.

There was an additional secondary aim involving metformin:

* To evaluate the impact of the diabetes risk reduction intervention in terms of women seeking out their physician's advice on metformin treatment and receiving a metformin prescription, if appropriate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Weight Reduction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Weight reduction Behavioral intervention Gestational diabetes mellitus Type 2 diabetes Diabetes testing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Weight Reduction Intervention

Group Type EXPERIMENTAL

Weight Reduction Intervention

Intervention Type BEHAVIORAL

The weight trial intervention components were:

* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).
* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.
* Print mailings/emailings
* 3 Get Ready e-messages in the four weeks before the weight intervention began
* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)
* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals.

Weight Reduction Control Arm

Group Type ACTIVE_COMPARATOR

Weight Reduction Control Arm

Intervention Type BEHAVIORAL

Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.

Tested for diabetes

Group Type ACTIVE_COMPARATOR

Tested for diabetes

Intervention Type BEHAVIORAL

Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.

Not tested for diabetes

Group Type ACTIVE_COMPARATOR

Not tested for diabetes

Intervention Type BEHAVIORAL

Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weight Reduction Intervention

The weight trial intervention components were:

* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).
* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.
* Print mailings/emailings
* 3 Get Ready e-messages in the four weeks before the weight intervention began
* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)
* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals.

Intervention Type BEHAVIORAL

Weight Reduction Control Arm

Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.

Intervention Type BEHAVIORAL

Tested for diabetes

Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.

Intervention Type BEHAVIORAL

Not tested for diabetes

Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

General

* History of GDM in the previous 6 months to 4.5 years
* Access to the internet and text messages or phone messages
* Current patient of Harvard Vanguard Medical Associates
* 18 years of age or older
* Able to read in English

Weight Reduction Group

* Overweight or obese
* Capable of performing moderate physical activity

Diabetes Testing Group

* Had not competed a diabetes test (OGTT or fasting blood sugar at 6-12 weeks postpartum or OGTT, fasting blood sugar or hemoglobin A1c after 12 weeks postpartum)

Exclusion Criteria

General:

* Diabetes diagnosis
* Psychotic disorder diagnosis
* Enrolled in a research study

Weight Reduction Group

* Taking prescription medications for weight loss
* Engaged in a formal weight reduction program

Diabetes Testing Group

* History of postpartum OGTT, fasting plasma glucose or hemoglobin A1c (after 6 weeks postpartum)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Harvard Pilgrim Health Care

OTHER

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role collaborator

Harvard Vanguard Medical Associates

OTHER

Sponsor Role collaborator

Social & Scientific Systems Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susan J Griffey, DPh, BSN

Role: PRINCIPAL_INVESTIGATOR

Social & Scientific Systems Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Social & Scientific Systems Inc.

Silver Spring, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Paez KA, Griffey SJ, Thompson J, Gillman MW. Validation of self-reported weights and heights in the avoiding diabetes after pregnancy trial (ADAPT). BMC Med Res Methodol. 2014 May 13;14:65. doi: 10.1186/1471-2288-14-65.

Reference Type DERIVED
PMID: 24886128 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GS10F0381L

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

NDEP-GDM GS10F0381L

Identifier Type: -

Identifier Source: org_study_id